U.S. markets closed
  • S&P Futures

    3,606.75
    +5.25 (+0.15%)
     
  • Dow Futures

    28,888.00
    +87.00 (+0.30%)
     
  • Nasdaq Futures

    11,012.00
    -23.50 (-0.21%)
     
  • Russell 2000 Futures

    1,674.30
    +4.50 (+0.27%)
     
  • Crude Oil

    81.98
    +2.49 (+3.13%)
     
  • Gold

    1,671.40
    -0.60 (-0.04%)
     
  • Silver

    19.10
    +0.07 (+0.35%)
     
  • EUR/USD

    0.9806
    -0.0013 (-0.14%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1160
    +0.0036 (+0.33%)
     
  • USD/JPY

    144.7540
    +0.3110 (+0.22%)
     
  • BTC-USD

    19,199.18
    -122.37 (-0.63%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.89 (-1.84%)
     

Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference

·1 min read
Windtree Therapeutics
Windtree Therapeutics

WARRINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022.

The presentation will be available on demand beginning at 7:00 am ET on Monday, September 12th. To view the presentation or request a 1x1 meeting, click HERE to register and attend the event or contact your H.C. Wainwright representative.

About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Contact Information:
Monique Kosse
LifeSci Advisors
212.915.3820 or monique@lifesciadvisors.com

Media contact:
Katie Larch / Robert Flamm, Ph.D.
Burns McClellan, Inc.
klarch@burnsmc.com / rflamm@burnsmc.com